Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned an average rating of “Hold” from the twenty-five research firms that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $101.48.

ALNY has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $85.00 price objective (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price on the stock in a report on Wednesday, July 12th. BMO Capital Markets restated an “outperform” rating and issued a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 6th. Piper Jaffray Companies restated an “overweight” rating and issued a $110.00 target price (down previously from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Finally, Instinet initiated coverage on shares of Alnylam Pharmaceuticals in a report on Friday, September 15th. They issued a “reduce” rating and a $56.00 target price on the stock.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) traded down 0.80% during trading on Friday, hitting $114.70. The stock had a trading volume of 1,310,104 shares. Alnylam Pharmaceuticals has a 1-year low of $31.38 and a 1-year high of $126.16. The firm has a 50-day moving average of $105.19 and a 200 day moving average of $79.74. The company’s market capitalization is $10.52 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter in the prior year, the company posted ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% on a year-over-year basis. Equities research analysts predict that Alnylam Pharmaceuticals will post ($5.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Receives Consensus Recommendation of “Hold” from Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/22/alnylam-pharmaceuticals-inc-alny-receives-consensus-recommendation-of-hold-from-brokerages.html.

In other news, President Barry E. Greene sold 85,316 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Barry E. Greene sold 76,815 shares of the stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares of the company’s stock, valued at $16,539,900. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. QS Investors LLC grew its position in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares during the period. Prudential Financial Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at approximately $215,000. CIBC Asset Management Inc bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $221,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $229,000. 94.25% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.